摘要:
The invention describes a novel pharmaceutical preparation for treating IRDS or ALI, comprising at least one modification of surfactant protein B (SP-B) and at least one modification of surfactant protein C (SP-C).
摘要:
Composition for the treatment of infant or adult respiratory distress syndrome (IRDS and ARDS) contains N-(3,5-dichloropyrid-4-yl)-3- cyclopropylmethoxy-4- difluoromethoxybenzamide (II) (and/or its salts) and a lung surfactant.
摘要:
Novel compositions are disclosed for the treatment of IRDS and ARDS, containing at least one glucocorticosteroid and a pulmonary surfactant. The duration of treatment and the mortality associated with these syndromes can be significantly reduced with the proposed novel compositions.
摘要:
The invention describes a set for the treatment of IRDS, ALI or ARDS, comprising a first container which has a volume of 50 to 500 ml and contains a pulverulent pulmonary surfactant preparation, the amount of phospholipids in the container being 50 to 500 mg, and a second container which has a volume of 50 to 500 ml and contains a pulverulent pulmonary surfactant preparation, where the amount of phospholipids in the second container is 1 to 10 g.
摘要:
Novel compositions for the treatment of IRDS and ARDS are indicated which contain a compound of formula (I), in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt of this compound and lung surfactant.